According to Aaron Pearson, he is Vice President of Public Relations at Stratasys 3D Printing, “The need for widespread COVID-19 testing of millions of people has surfaced another shortage, nasal swabs. Stratasys has added to its efforts to fight the pandemic and ongoing testing requirements by marketing and promoting Origin 3D-printed nasopharyngeal (NP) swabs to healthcare providers and other testing centers in the U.S. The Origin 3D-printed nasopharyngeal swab has been tested in a clinical trial and is considered an FDA Class I Exempt Device.”
This entry was posted in 3D Printing and biofabrication., 3D Printing challenges, Housing construction., 3D Printing information., 3D Printing Market share., 3D Printing services., 4D and 3D Printing in the Healthcare market., Network of 3D printing researchers., SV3DPrinter.com Policy. and tagged Aaron Pearson, FDA, nasal swabs, Nasal swabs and COVID-19 testing: the next step in the Stratasys pandemic response., Stratasys 3D Printing, Stratasys is helping nasal swabs and COVID-19 testing.